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a b s t r a c t
To better understand vaccine-induced protection and its potential failure in light of recent whooping
cough resurgence, we evaluated quantity as well as quality of memory T cell responses in B. pertussis-
vaccinated preadolescent children. Using a technique based on ﬂow cytometry to detect proliferation,
cytokine production and phenotype of antigen-speciﬁc cells, we evaluated residual T cell memory in
a cohort of preadolescents who received a whole-cell pertussis (wP; n=11) or an acellular pertussis
vaccine (aP; n=13) during infancy, and with a median of 4 years elapsed from the last pertussis booster
vaccine, which was aP for all children. We demonstrated that B. pertussis-speciﬁc memory T cells are
detectable in the majority of preadolescent children several years after vaccination. CD4+ and CD8+ T
cell proliferation in response to pertussis toxin and/or ﬁlamentous hemagglutinin was detected in 79%
and 60% of the children respectively, and interferon- or tumor necrosis factor- producing CD4+ T cells
were detected in 65% and 53% of the children respectively. Phenotyping of the responding cells showed
that the majority of antigen-speciﬁc cells, whether deﬁned by proliferation or cytokine production, were
CD45RA−CCR7− effectormemoryTcells. Although the timesince the last booster vaccinewas signiﬁcantly
longer for wP-compared to aP-vaccinated children, their proliferation capacity in response to antigenic
stimulationwas comparable, andmore childrenhadadetectable cytokine response afterwP-compared to
aP-vaccination. This study supports at the immunological level recent epidemiological studies indicating
that infant vaccination with wP induces longer lasting immunity than vaccination with aP-vaccines.
201©Abbreviations: aP, acellular pertussis; Bp, Bordetella pertussis; FHA, ﬁlamentous
emagglutinin; PBMC, peripheral blood mononuclear cells; PT, pertussis toxin; SEB,
taphylococcus enterotoxin B; wP, whole-cell pertussis.
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1. Introduction
Pertussis continues to be the most poorly controlled bacterial
vaccine-preventable disease despite high levels of vaccine cover-
age. Since the 1980s, different pertussis epidemics have arisenwith
a high burden of disease among teenagers, a group that previ-
ously had a low risk of pertussis [1–4]. Increased awareness and
improved diagnostics coincide with increased notiﬁcation of per-
tussis, but do not completely account for it. Multiple factors may
Open access under CC BY-NC-ND license.contribute to this true resurgence, including waning of vaccine-
induced immunity. Waning can result from less circulation of the
pathogen and, as a consequence, less natural boosting. However, in
the same timeframe whole-cell pertussis (wP) vaccines were, due
 license.
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o their reactogenicity, replaced by acellular (aP) vaccines in most
eveloped countries. Therefore, vaccine efﬁcacy and more speciﬁ-
ally the quality of the initial immune response induced by current
accines have been called into question [3,5–8]. Recent epidemio-
ogical evidence indicates that aP-induced immunity wanes faster
han that induced bywP vaccination, showing that the current vac-
ination strategies against pertussis are not optimal for long-term
rotection [9–11].
Even if serum antibodies are important for protection against
hooping cough, their levels decline rapidly after vaccination,
hile protection against severe disease lasts longer [12]. Several
tudies have demonstrated that cell-mediated immune mecha-
isms involving individual T and B cell populations are implicated
s well [12–14]. The contribution of T cells to protection was
emonstrated in animal models [15–21], and the appearance of
. pertussis (Bp)-speciﬁc T lymphocytes soon after infection or vac-
ination is well recognized [22–25], as well as the importance for
rotection of bothmagnitude and quality of the immune responses
26]. Therefore, in the context of the current re-emergence of per-
ussis in countries with high vaccination coverage, exploring in
etail the long-termTcell responses inducedbyvaccinationmaybe
f interest. Because several years after vaccination the frequency of
irculating antigen-speciﬁc cells is low,we have developed a sensi-
ive technique that allows expansion of the responsive population.
e then examined the T cell responses in a cohort of 9- to 12-
ear-old children, vaccinated in their infancy with either wP- or
P-vaccines.
. Methods
.1. Study participants
Blood samples were collected from seven healthy adults who
adbeenvaccinatedwithBoostrix 1–14months before for the opti-
ization of the technique, and from 23 children with a median age
f 10.1 years (range 9.0–12.1). As a consequence of changes in the
elgian vaccination recommendations, 11 children received thewP
accines Tetracoq (SanoﬁPasteur, Lyon, France) orCombivax (Glax-
SmithKline, Rixensart, Belgium) whereas the aP vaccine Tetravac
Sanoﬁ Pasteur) was given to 12 children. The median age at which
ach of the doses was administered, was 3.23 (dose 1), 4.57 (dose
), 5.57 (dose 3) and 14.3 months (dose 4) respectively. All chil-
ren received an aP booster vaccine (Tetravac or Infanrix-IPV from
laxoSmithKline) between 5.5 and 8.2 years of age, and themedian
ime elapsed between the booster and this studywas 4 years (range
.8–5.5 years). There was a signiﬁcant difference between the time
fter the last booster vaccine for wP compared to aP vaccinated
hildren (median=4.8 year forwP-versus2.7 year for aP-vaccinated
hildren; p=0.004). The ethical committees of Hôpital Erasme and
niversitair Ziekenhuis Brussel (Brussels, Belgium) approved the
tudy andparticipants or their parents signed the informed consent
orms.
.2. Antigens and mitogen for cellular immune assays
Tetravac, the aP vaccine used for infant vaccination in this study,
ontains 2 Bp antigens, ﬁlamentous hemagglutinin (FHA) and per-
ussis toxin (PT). These antigens were therefore selected for the
ellular immune assays. FHA and PT were puriﬁed from crude
aterial obtained from Novartis (Siena, Italy), as described [27].
oth antigens were heat inactivated at 96 ◦C for 15min and used
t a ﬁnal concentration of 10g/mL and 5g/mL respectively,
s determined by previous optimization studies. Staphylococcus
nterotoxin B (SEB) (Sigma–Aldrich, St. Louis, MO) was used as a
ositive control at 0.5g/mL.2 (2014) 111–118
2.3. PBMC isolation
Peripheral blood mononuclear cells (PBMC) were isolated from
whole blood by density gradient centrifugation over Lymphoprep
(Nycomed Pharma, Oslo, Norway), and immediately cultured at
2×106 cells/mL in supplemented RPMI culture medium (Biowhit-
taker, Verviers, Belgium) (complete medium) as described before
[22].
2.4. Combined cell proliferation and intracellular cytokine
staining assay
Weoptimized a ﬂow cytometry-based assay for the detection of
Bp-speciﬁc memory T cells present in low amounts, which involves
a long in vitro stimulation with the Bp-antigens FHA and PT (see
Supplemental Information for detailed information). Brieﬂy, PBMC
were labeled with carboxyﬂuorescein succinimidyl ester (CFSE,
Vybrant CFSDA-SE cell tracer kit, Invitrogen, Merelbeke, Belgium)
as previously described [27,28], resuspended at 2×106 cells/mL
and cultured for 5 days in the presence of antigen. Brefeldin-A
(Sigma–Aldrich, 10g/mL) was added for the last 4h of incuba-
tion. Cells were then incubated for 15min at room temperature
in the presence of EDTA (2mM), and washed with PBS. Dead cells
were identiﬁed by using the Live/dead ﬁxable Aqua dead cell stain
kit (Invitrogen) and the PBMC were stained with the following
anti-human monoclonal antibodies: CCR7 PE (clone FAB197P, R&D
Systems, Abingdon, UK), CD45RA PE-Cy7 (clone L48) and CD4 APC-
H7 (clone SK3, both fromBDBiosciences,Mountain View, CA, USA).
The cells were ﬁxed and permeabilized using Lysing Solution 1
and Permeabilizing Solution 2 (BD Biosciences) according to the
manufacturers’ instructions, and subsequently stained with the
following anti-human monoclonal antibodies: IFN- APC (clone
25723.11), CD3V450 (cloneUCHT1) (both fromBDBiosciences) and
TNF- PerCP/Cy5.5 (clone MAb11, Biolegend, San Diego, CA). Cells
were acquired on a FACSCanto ﬂow cytometer (BD Biosciences),
and the data were analyzed using the FlowJo software (Tree Star,
Ashland, OR). A median of 60,000 cells was acquired (interquar-
tile range 39,000–82,000). A subject was considered responsive
when his antigen-induced response was 2 times higher than the
value obtained for the unstimulated cells from the same subject
and higher than the median value obtained for the unstimulated
cells of all subjects.
2.5. Statistical analysis
Data were analyzed using the GraphPad Prism version 4.00 for
Windows (GraphpadSoftware, SanDiego,CA,www.graphpad.com)
or the IBM SPSS statistics version 19 (Chicago, IL). We used non-
parametric tests to compare independent data (Mann–Whitney)
andpaired samples (Wilcoxonsigned rank test). SPICE (MarioRoed-
erer, VaccineResearchCenter, NIAID,NIH)wasused to compare the
phenotypic proﬁles of responding cells [29].
3. Results
3.1. Bp-speciﬁc T cell proliferation in wP- and aP-vaccinated
children
We evaluated T cell proliferation of CD3+CD4+ and CD3+CD4−
cells, further referred to as CD4+ and CD8+ T cells for simplicity,
in response to Bp-antigens. Both FHA and PT were able to elicit a
T cell response in vitro in a subset of the vaccinated children, by
measuring the frequency of CFSEdim cells (Supplementary Figure
2C, green gate). For the proliferation of CD4+ T cells, the response
to FHA was signiﬁcantly higher from that of unstimulated con-
trols, both for wP- and aP-vaccinated children (Wilcoxon signed
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Fig. 1. T cell immune response to B. pertussis antigens FHA and PT in 9 to 12-years-old wP (open circles) or aP (closed circle) vaccinated children, as evaluated by antigen
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Cpeciﬁc proliferation of CD4 (A–B) or CD8 cells (C–D). Each line represents the respo
g) of antigen. Statistically signiﬁcant differences are indicated (*, p<0.05; **, p<0.
ank test, p<0.05 and p<0.01) (Fig. 1A and B). For the CD8+ T
ells, in addition to a signiﬁcant proliferation in response to FHA
oth in wP- and aP-vaccinated children (p<0.01), a response to
T was observed for wP-vaccinated children (p<0.05) (Fig. 1C and
). These results indicated that, although the time since the last
ooster vaccine was signiﬁcantly longer for wP-compared to aP-
accinated children, the proliferation capacity of wP-vaccinated
hildren in response to antigenic stimulation was at least as good
s the response observed for aP-vaccinated children. Globally, the
ajority of the children were able to respond by CD4+ T cell pro-
iferation to at least one of the tested Bp antigens (79%, see Section
.4 for deﬁnition of responder), while 60% of them responded by
D8+ T cell proliferation (Table 1).f an individual in the presence (FHA in A and C; PT in B and D) or in the absence (no
ilcoxon rank test).
3.2. Bp-speciﬁc cytokine production in wP- and aP-vaccinated
children
We compared Bp-speciﬁc cytokine responses of wP- and aP-
vaccinated children. The nonspeciﬁc background was determined
by culturing the PBMC from the same subject, for the same period
in the absence of antigen, and all results are background subtracted.
The frequencyofCD4+ cells producing IFN- in response to FHAwas
signiﬁcantly higher for wP-compared to aP-vaccinated children
(Mann–Whitney, p<0.01), while this difference was not signiﬁ-
cant for PT (Fig. 2A). Antigen-speciﬁc production of TNF-was also
noted for a subset of vaccinated children but no signiﬁcant differ-
ences appeared between wP- and aP-vaccinated children (Fig. 2B).
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Table 1
Frequency of responders for wP- and aP-vaccinated children.
Vaccine type Response Proliferation
CD3+CD4+ cells
Proliferation
CD3+CD4- cells
Cytokine prod
CD3+CD4+ cells
Prolif and cytokine
prod CD3+CD4+ cells
FHA PT FHA PT FHA PT FHA PT
wP Respondera 6 3 6 3 6 6 5 3
Total tested 9 10 9 10 9 10 9 10
Freq responders (%) 67 30 67 30 67 60 56 30
aP Responder 8 4 4 4 3 4 3 2
Total tested 11 11 11 11 11 11 11 11
Freq responders (%) 73 36 36 36 27 36 27 18
Allb Responder 14 7 10 7 9 10 8 5
Total tested 20 21 20 21 20 21 20 21
Freq responders (%) 70 33 50 33 45 48 40 24
Responder FHA or PT 15 12 13 8
Total tested 19 20 20 17
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aFreq responders (%) 79
a See Section 2.4 for deﬁnition of responder.
b All wP- or aP-vaccinated children.
lobally, cytokine production of CD4+ T cells in response to at least
antigen (FHA and/or PT) was detected in 65% (IFN-) and 53%
TNF-) of the children (see Section 2.4 for deﬁnition of a respon-
er). The frequencies of cytokine producing CD8+ T cells were low
s illustrated inFig. 2C for IFN-, so that classiﬁcationof the subjects
n responders and non-responders was not possible.
When the twovaccine typeswere compared for their capacity to
nduce cytokine production in response to one or both Bp-antigens,
alf of the aP-vaccinated children appeared to be unable to induce
cytokine response to any antigen, in contrast to only 12% for wP-
accinated children (Fig. 3). Due to small sample size, no statistical
nalysis was performed.
.3. Combined analysis of proliferation and cytokine production
n response to Bp antigens
If a child was considered responsive to an antigen when either
roliferation or cytokine production was positive, 75% and 57% of
he childrenwere responsive to FHA and PT, respectively. However,
e further examined whether proliferation and cytokine produc-
ion identiﬁed the same group of children as responders or not. For
HA, a large subset of children showedproliferation, andwithin this
roup of responders, a smaller subset also produced cytokines. The
ppositewas found for PT,with a large subset of childrenproducing
ytokines, from which half of the children also had proliferat-
ng cells (Fig. 4A). In addition to these antigen-linked differences,
P-vaccinated children more frequently respond with both pro-
iferation and cytokine-production compared to aP-vaccinated
hildren in response to FHA and PT (Table 1).
Differences between PT and FHA were also observed when
he quality of the responses was examined within the group of
hildren with cytokine responses. The frequency of CD4+ cells
hat produced both IFN- and TNF- (DP, double positive cells)
mong all cytokine producing cells (Supplementary Figure 2C,
range gate) was higher in response to FHA than in response to
T (Mann–Whitney, p<0.01)(Fig. 4B)..4. Phenotype of antigen-speciﬁc cells
The majority of the 9- to 12-years old children responded to
t least one of the tested Bp-antigens, and we characterized the60 65 47
phenotypic proﬁle of antigen-speciﬁc CD4+ T cells that have been
identiﬁed by antigen-speciﬁc proliferation or cytokine production.
For CD8+ T cells we were limited to the evaluation of the pheno-
typic proﬁle of proliferating cells, as the frequencies of cytokine
producing CD8+ T cells were too low to allow classiﬁcation of the
subjects in responders and non-responders (Fig. 2C). CD4+ or CD8+
T cells cultured for the sameperiodof time in the absence of antigen
stimulation were used as control (Fig. 5A and B).
Themost frequent phenotype found in proliferating CD4+ T cells
(Fig. 5C), as well as cytokine-producing CD4+ T cells (IFN- and/or
TNF-, Fig. 5D), were CD45RA− CCR7− effector memory cells. This
population was signiﬁcantly enriched at the expense of naive cells,
when compared to unstimulated controls (Wilcoxon signed rank
test, p<0.001, Supplementary Table 1). We found no signiﬁcant
differences between phenotypic proﬁles of wP- and aP-vaccinated
children (Fig. 5C, Supplementary Table 2). CD45RA−CCR7+ CD4+
central memory cells were also detected, but their frequency was
not different compared to unstimulated cells. The phenotype of
proliferating CD8+ T cells was signiﬁcantly different from that
of unstimulated controls (Fig. 5B and E), with a dominance of
CD45RA−CCR7− CD8+ effector memory cells. When the pheno-
types of the cells induced by the different antigens were compared,
there was no signiﬁcant difference, neither for proliferation nor for
cytokine production (Supplementary Table 1).
4. Discussion
The reasons for waning of vaccine-mediated immunity against
pertussis in human are poorly understood. The role of antibod-
ies in protection is well known, with evidence provided from
humanstudies showingan inverse correlationbetweenserumanti-
body levels and incidence of severe pertussis [30–33], and from
murine studies with protection afforded by passive transfer of
antibodies [16,34]. However, persistence of detectable antibody
levels is relatively short, and can therefore not explain long-term
protection. More recently it was shown that vaccination induces
antigen-speciﬁc memory B cells, still detectable several years after
vaccination despite waning antibody levels [35,36]. Moreover, the
induction upon infection or vaccination of distinct T cell popula-
tions, TH1, TH17, TH2 and regulatory T cells, has been established in
animal models, as well as their role in protection [15–21]. We have
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ntigen speciﬁc cytokine production. Relative frequency of CD4+ (A–B) or CD8+ (C) ce
ars correspond to median percentage of cytokine producing cells (n=11 for wP; n
reviously shownthat inhumans, distinct T cell subsets are induced
hortly after vaccination or infection [22–25], and here we show
hat several years after vaccination, memory T cells with mainly
n effector memory phenotype (CD45RA−CCR7−) are detected in a
igh percentage of 9- to 12-years old children. Upon in vitro stim-
lation, these cells proliferate (79% of the children) and produce
ytokines (65%) in response to at least one of the antigens PT or
HA. In 60% of the children, we could also detect proliferation of
D8+ T cells in response to PT and/or FHA stimulation, supporting
role of CD8+ T cells in Bp-speciﬁc immunity, in line with our pre-
ious ﬁnding that FHA-speciﬁc CD8+ T cells contribute to IFN-
roduction [37].
Recent epidemiological studies in several countries with high
accination coverage have indicated that teenagers who received
n aP vaccine as an infant were more at risk to develop pertussisildren, vaccinated with a whole cell (wP) or acellular (aP) vaccine, as evaluated by
t produce IFN- (A and C) or TNF- (B). Data are background subtracted. Horizontal
r aP). **Statistically signiﬁcant differences (p<0.01; Wilcoxon rank test).
than wP primed children [2,9,38,39]. Other studies suggest that
this is due to a more rapid waning of aP compared to wP vaccine-
induced immunity and have shown that the rate of vaccine failure
gradually increases as the interval from the last aP vaccine dose
increases [10,11]. In our study, we demonstrated that the vac-
cine type used for primary vaccination inﬂuences the immune
response detected in 9- to 12-year old children. Cytokine response
were broader afterwP vaccination,with 88% ofwP-vaccinated chil-
dren being positive for PT- or FHA-induced cytokine responses,
while this was the case only for 50% of the aP-vaccinated chil-
dren. Also, the PBMC fromwP-primed children proliferated equally
well in response to Bp antigens compared to aP-primed children,
although the time since the last booster was longer in the former
group. The frequency of children responding with both prolifera-
tion and cytokine production is twice as high for wP-compared to
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Fig. 3. Overview of B. pertussis immune response to multiple antigens according
to vaccine type. Relative distribution of wP (left) or aP (right) vaccinated children,
evaluated for their ability to respond with cytokine production (IFN- or TNF-) to
one, two or none of the following antigens: FHA and PT. See Section 2 for deﬁnition
of a positive response (n=8 for wP; n=10 for aP).
Fig. 4. Parameters of the immune response that vary according to the antigen used
for stimulation. (A) Distribution of type of response for FHA (n=20) and PT (n=21).
(B) Relative frequency of IFN-+ TNF-+ double positive (DP) cells among all CD4+
cytokine producing cells, among responders (n=9 for FHA; n=10 for PT) (Section
2.4 for deﬁnition). **Statistically signiﬁcant differences (p<0.01; Mann–Whitney).2 (2014) 111–118
aP-vaccinatedchildren. Thus, for theﬁrst time,weprovideevidence
that recently revealed differences in protection may be traced back
to differences at the immunological level, both showing that wP-
vaccines compare favorably to aP-vaccines. Although we cannot
provide a direct link between the presence of the tested parameters
and the fact that a particular child is protected or not, both ﬁndings
support the hypothesis that waning is caused by a difference in
quality of the initial immune response, and not solely by a reduc-
tion of natural boosting as a consequence of good vaccine coverage.
Whether the parameters we evaluated are the only ones that dif-
fer after administration of the two vaccine types, we do not know.
Other parameterswithin the T cell compartment could be involved,
like TH17 cells. Their role in protection was suggested from murine
studies, in which aP vaccination induces TH2 and TH17 responses,
but only the latter seem necessary for protection [20]. However,
the situation in humans is quite different, as after aP vaccination
a mixed TH1–TH2 phenotype is observed, therefore not excluding
a role for TH1 in protection [12]. Moreover, B cell memory might
also be inﬂuenced by vaccine type. Dutch studies show that wP
vaccinated children have detectable B cell memory responses up to
5 years after the last booster dose [35,40]. However, up to 2 years
after abooster vaccine, childrenwhoreceivedaPvaccines at infancy
induced better B cell memory responses compared to those primed
with a wP vaccine [41,42]. As protection appears to be better for
wP vaccinated children [2,9,38,39], this supports the hypothesis
that B cell memory is not the limiting factor for protection for the
currently used vaccines.
Even though the cohorts included here are relatively small, an
important strength of this study was that we obtained the precise
records of all the vaccine data for all the children. However, we
cannot rule out that some of the children may have boosted their
immune responses by natural exposure to Bp, even if none of the
children declared having suffered from whooping cough or hav-
ing been in contact with a whooping cough patient. Serum levels
of Bp-speciﬁc antibodies that were measured as part of a study on
memory B cell responses and will be published separately, indi-
cated that out of the 23 children in this study, only one had an
elevated anti-PT IgG serum level, a marker for recent infection
(>125 IU/mL, data not shown) [43,44]. This subject belonged to the
group of wP-vaccinated children, but sensitivity analysis revealed
that this did not impact the described differences betweenwP- and
aP-vaccinated children. It is therefore unlikely that the results in
this study have been confounded by natural boosting of pertussis-
speciﬁc immune responses.
We also found antigen-dependent differences in the memory
immune responses. More children responded by proliferation or
cytokine production to stimulation with FHA compared to PT. It
should be noted that only PT is speciﬁc for Bp, while responses to
FHA might also be the result of exposure to other Bordetella species
or cross-reactivity with other bacteria, including Haemophilus
inﬂuenza [45]. The observed difference may thus potentially be
due to non-speciﬁc boosting. Nevertheless, it remains of interest
to examine the FHA-speciﬁc immune response for the compari-
son of different vaccines, as differences in the observed immune
responses may reﬂect differences induced by primary vaccination.
Natural boosting by exposure to micro-organisms producing FHA-
like molecules might thus have different consequences depending
on the primary vaccination with pertussis vaccines.
Besides antigen-related differences in the frequency of res-
ponding children, we also observed qualitative differences in the
types of immune responses. Proliferation occurred in the absence
of cytokine production for FHA, while for PT we observed the
opposite, in addition to children responding by proliferation and
cytokineproduction forbothantigens. Furthermore,whencytokine
responses were detectable, the relative frequency of double posi-
tive IFN-+ TNF-+ cells was higher for FHA than for PT.
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Fig. 5. Phenotype proﬁles. Phenotype subsets of bulk CD4 (panel A) or CD8 (panel B) cells observed after 5 days of culture in the absence of antigenic stimulation (unstimulated
controls). Pie slices correspond to median of the population depicted in the graph below. Phenotype proﬁle of antigen speciﬁc CD4 cells, as deﬁned by proliferation (panel C)
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anels C–E are positive responders (see Section 2.4 for deﬁnition). Color of dots refe
n this legend, the reader is referred to the web version of the article.)
Regardless of the readout (proliferation or cytokine production)
r the antigen used for stimulation (FHA versus PT), the distribution
f phenotypically distinct populations of responding cellswas com-
arable. The majority of the responding cells were CD45RA−CCR7−
ffector memory cells and to a lesser extent CD45RA−CCR7+ cen-
ral memory cells. Due to the long incubation time it is possible
hat culture conditions may have impacted the presence of phe-
otypic markers, and that some markers, such as CCR7, may have
een lost during culture. However, a shorter incubation time was
ot sufﬁcient for the detection of antigen-speciﬁc responses many
ears after the last vaccine dose, and therefore we were unable
o show that the phenotype is unchanged during ampliﬁcation.
evertheless, our results are in line with those of Sharma and
ichichero [46] showing effector memory cells that were induced
hortly after vaccination in a short-term assay. The phenotype
f effector memory cells was dominant in all responding sub-
opulations, CD4+ and CD8+, and we observed no vaccine-related
ifferences.
In conclusion, we show here that Bp-speciﬁc memory T cells
re detectable in preadolescent children several years after the
ast booster vaccine, but that both the magnitude and the qual-
ty of the T cell responses differ between children that had received
he wP vaccine and those that had received the aP vaccine duringﬁle of antigen speciﬁc CD8 cells, as deﬁned by proliferation. Subjects presented in
ype of vaccine (wP in blue; aP in red). (For interpretation of the references to color
the primary vaccination course. The different degrees of protection
between these two types of vaccines may therefore perhaps be the
consequence of these immunological differences, and merits larger
scale studies.
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